Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.
Lupus: Closer to a Cause?
Two studies outline the roles of air pollution and T cell imbalance in the pathogenesis of systemic lupus erythematosus.
The Rheumatologist’s Role in Sarcoidosis
Rheumatologists are uniquely positioned to care for patients with sarcoidosis. Here are insights into the condition, its treatment and more.
A World View: The ACR Global Research Exchange Program Promotes Mentorship & Long-Term Collaboration in Rheumatology
2023 marks the post-pandemic return of research exchanges hosted by the ACR & EULAR to benefit junior academic rheumatologists & rheumatology professionals.
The Importance of Health Literacy in Clinical Care
EULAR 2023—It is not enough to practice medicine by the book; rather, communication with patients and understanding their goals for patients are vital to high-quality care. At EULAR 2023, the session titled The Promise of Health Literacy in Clinical Care provided a treasure trove of insights for many clinicians. Definitions & Actions The first speaker…
Point-of-Care Uric Acid Testing
In June 2022, I listened to several presentations on gout at EULAR’s European Congress of Rheumatology. Most began with data confirming a sad truth that we, as rheumatology providers, are all aware of: too many patients are taking subtherapeutic doses of urate-lowering therapy (ULT).1,2 Recommendations from the American College of Physicians in 2017 advocated for…
Zoledronic Acid vs. Oral Bisphosphonates: Osteoporosis Treatments & the Risk of Developing Osteonecrosis of the Jaw
A study from Amigues et al. found that bisphosphonate-associated osteonecrosis of the jaw is rare in patients with osteoporosis and may occur more often in patients treated with injectable zoledronic acid than in those treated with the oral bisphosphonates.
Difficult-to-Treat RA Definition & Management Considerations
Despite an expanding armamentarium of disease-modifying treatments for rheumatoid arthritis (RA), some patients with RA remain symptomatic.1 Current treatment guidelines from both the ACR and the European Alliance of Associations for Rheumatology (EULAR) recommend treat-to-target strategies to achieve remission or low disease activity, and patients want to feel better.2,3 So how can we best help…
TNF Inhibitors Associated with Neurological Adverse Events
A study examined the association between TNF inhibitors and neurological demyelinating adverse events in patients with rheumatoid arthritis and spondyloarthritis using cohort data from five Nordic countries. Researchers showed that patients with SpA were more likely to experience adverse events than patients with RA.
What’s New in SLE: Pathogenesis & Novel Therapies
Thomas Dörner, MD, reviewed the current state of systemic lupus erythematosus (SLE) management, providing updates on novel therapies and insights into the pathogenesis of SLE.
- 1
- 2
- 3
- …
- 16
- Next Page »